^
    Back
    Association details:
    Biomarker:HER-2 expression
    Cancer:Non Small Cell Lung Cancer
    Drug:PF-06804103 (Microtubule inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Mol Cancer Ther
    Title:

    PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers

    Excerpt:
    ...we evaluated the in vivo activity of PF-06804103 in a panel of HER2-expressing gastric...and non–small cell lung...cancer PDX models. In the PDX-GAX-0044 (Fig. 3G) and PDX-NSX-26110 (Fig. 3I) models, PF-06804103 resulted in sustained tumor regressions as compared with PT-DM1.
    DOI:
    https://doi.org/10.1158/1535-7163.MCT-20-0237